30
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Mapping the Homodimer Interface of an Optimized, Artificial, Transmembrane Protein Activator of the Human Erythropoietin Receptor

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Transmembrane proteins constitute a large fraction of cellular proteins, and specific interactions involving membrane-spanning protein segments play an important role in protein oligomerization, folding, and function. We previously isolated an artificial, dimeric, 44-amino acid transmembrane protein that activates the human erythropoietin receptor (hEPOR) in trans. This artificial protein supports limited erythroid differentiation of primary human hematopoietic progenitor cells in vitro, even though it does not resemble erythropoietin, the natural ligand of this receptor. Here, we used a directed-evolution approach to explore the structural basis for the ability of transmembrane proteins to activate the hEPOR. A library that expresses thousands of mutants of the transmembrane activator was screened for variants that were more active than the original isolate at inducing growth factor independence in mouse cells expressing the hEPOR. The most active mutant, EBC5-16, supports erythroid differentiation in human cells with activity approaching that of EPO, as assessed by cell-surface expression of glycophorin A, a late-stage marker of erythroid differentiation. EBC5-16 contains a single isoleucine to serine substitution at position 25, which increases its ability to form dimers. Genetic studies confirmed the importance of dimerization for activity and identified the residues constituting the homodimer interface of EBC5-16. The interface requires a GxxxG dimer packing motif and a small amino acid at position 25 for maximal activity, implying that tight packing of the EBC5-16 dimer is a crucial determinant of activity. These experiments identified an artificial protein that causes robust activation of its target in a natural host cell, demonstrated the importance of dimerization of this protein for engagement of the hEPOR, and provided the framework for future structure-function studies of this novel mechanism of receptor activation.

          Related collections

          Most cited references65

          • Record: found
          • Abstract: not found
          • Article: not found

          Empirical predictions of protein conformation.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial.

            Anaemia is associated with poor cancer control, particularly in patients undergoing radiotherapy. We investigated whether anaemia correction with epoetin beta could improve outcome of curative radiotherapy among patients with head and neck cancer. We did a multicentre, double-blind, randomised, placebo-controlled trial in 351 patients (haemoglobin <120 g/L in women or <130 g/L in men) with carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx. Patients received curative radiotherapy at 60 Gy for completely (R0) and histologically incomplete (R1) resected disease, or 70 Gy for macroscopically incompletely resected (R2) advanced disease (T3, T4, or nodal involvement) or for primary definitive treatment. All patients were assigned to subcutaneous placebo (n=171) or epoetin beta 300 IU/kg (n=180) three times weekly, from 10-14 days before and continuing throughout radiotherapy. The primary endpoint was locoregional progression-free survival. We assessed also time to locoregional progression and survival. Analysis was by intention to treat. 148 (82%) patients given epoetin beta achieved haemoglobin concentrations higher than 140 g/L (women) or 150 g/L (men) compared with 26 (15%) given placebo. However, locoregional progression-free survival was poorer with epoetin beta than with placebo (adjusted relative risk 1.62 [95% CI 1.22-2.14]; p=0.0008). For locoregional progression the relative risk was 1.69 (1.16-2.47, p=0.007) and for survival was 1.39 (1.05-1.84, p=0.02). Epoetin beta corrects anaemia but does not improve cancer control or survival. Disease control might even be impaired. Patients receiving curative cancer treatment and given erythropoietin should be studied in carefully controlled trials.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses.

              We describe the construction and characterization of retroviral vectors and packaging plasmids that produce helper-free retrovirus with titers of 1 X 10(6) to 5 X 10(6) within 48 h. These vectors contain the immediate early region of the human cytomegalovirus enhancer-promoter fused to the Moloney murine leukemia virus long terminal repeat at the TATA box in the 5' U3 region, yielding the pCL promoter. By selecting vectors designed to express genes from one of four promoters (dihydrofolate reductase, Rous sarcoma virus, long terminal repeat, or cytomegalovirus), the pCL system permits the investigator to control the level of gene expression in target cells over a 100-fold range, while maintaining uniformly high titers of virus from transiently transfected producer cells. The pCL packaging plasmids lack a packaging signal (delta-psi) and include an added safety modification that renders them self-inactivating through the deletion of the 3' U3 enhancer. Ecotropic, amphotropic (4070A), and amphotropic-mink cell focus-forming hybrid (10A1) envelope constructions have been prepared and tested, permitting flexible selection of vector pseudotype in accordance with experimental needs. Vector supernatants are free of helper virus and are of sufficiently high titer within 2 days of transient transfection in 293 cells to permit infection of more than 50% of randomly cycling target cells in culture. We demonstrated the efficacy of these vectors by using them to transfer three potent cell cycle control genes (the p16(INK4A), p53, and Rb1 genes) into human glioblastoma cells.
                Bookmark

                Author and article information

                Contributors
                Role: Editor
                Journal
                PLoS One
                PLoS ONE
                plos
                plosone
                PLoS ONE
                Public Library of Science (San Francisco, USA )
                1932-6203
                2014
                30 April 2014
                : 9
                : 4
                : e95593
                Affiliations
                [1 ]Department of Genetics, Yale School of Medicine, New Haven, Connecticut, United States of America
                [2 ]Department of Molecular Biophysics & Biochemistry, Yale School of Medicine, New Haven, Connecticut, United States of America
                [3 ]Yale Cancer Center, New Haven, Connecticut, United States of America
                [4 ]Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut, United States of America
                [5 ]Department of Biochemistry and Cellular and Molecular Biology, University of Tennessee, Knoxville, Knoxville, Tennessee, United States of America
                University of Nebraska Medical Center, United States of America
                Author notes

                Competing Interests: 1. The authors received no support from a tobacco company. 2. Ms. Schwartz has no competing interests in relation to this work. 3. The authors are not aware of any competing interests.

                Conceived and designed the experiments: EBC SJJ FNB MA DME DD. Performed the experiments: EBC SJJ ZB FNB MA. Analyzed the data: EBC SJJ ZB FNB MA DME DD. Wrote the paper: EBC FNB DME DD.

                Article
                PONE-D-13-52501
                10.1371/journal.pone.0095593
                4005772
                24788775
                ff7a8cde-fe9f-4086-a582-d10d1fe5d2b7
                Copyright @ 2014

                This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

                History
                : 17 December 2013
                : 28 March 2014
                Page count
                Pages: 16
                Funding
                EBC was supported by training grants from the National Institutes of Health (DK007356 and AI055403) and an individual National Research Service Award from the National Cancer Institute (CA0168012). This work was supported by a grant to DD from the National Cancer Institute (CA037157) and a generous gift from Ms. Laurel Schwartz. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
                Categories
                Research Article
                Biology and Life Sciences
                Biochemistry
                Proteins
                Protein Interactions
                Proteomics
                Biophysics
                Biophysical Simulations
                Biotechnology
                Bioengineering
                Protein Engineering
                Cell Biology
                Cellular Structures and Organelles
                Cell Membranes
                Membrane Proteins
                Transmembrane Proteins
                Signal Transduction
                Cell Signaling
                Membrane Receptor Signaling
                Transmembrane Signaling
                Molecular Cell Biology
                Genetics
                Gene Identification and Analysis
                Genetic Screens
                Molecular Genetics
                Mutagenesis
                Mutation

                Uncategorized
                Uncategorized

                Comments

                Comment on this article